These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8092111)

  • 1. A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients.
    Kojima A; Shinkai T; Soejima Y; Okamoto H; Eguchi K; Sasaki Y; Tamura T; Oshita F; Ohe Y; Saijo N
    Am J Clin Oncol; 1994 Oct; 17(5):400-4. PubMed ID: 8092111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Imipenem/cilastatin sodium alone or combined with amikacin sulfate in respiratory infections].
    Takamoto M; Ishibashi T; Toyoshima H; Tanaka H; Tamaru N; Watanabe K; Yoshida M; Tokunaga N; Ichikawa Y; Oizumi K
    Jpn J Antibiot; 1994 Sep; 47(9):1131-44. PubMed ID: 7990255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimethoprim-sulfamethoxazole plus amikacin as first-line therapy and imipenem/cilastatin as second empirical therapy in febrile neutropenic patients with hematological disorders.
    Engervall PA; Stiernstedt GT; Günther GC; Björkholm MJ
    J Chemother; 1992 Apr; 4(2):99-106. PubMed ID: 1629753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients.
    Ozyilkan O; Yalçintaş U; Başkan S
    Korean J Intern Med; 1999 Jul; 14(2):15-9. PubMed ID: 10461420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer.
    Matsui K; Masuda N; Takada M; Kusunoki Y; Fukuoka M
    Jpn J Clin Oncol; 1991 Dec; 21(6):428-34. PubMed ID: 1805048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised study comparing imipenem/cilastatin to ceftriaxone plus gentamicin in cancer chemotherapy-induced neutropenic fever.
    Au E; Tow A; Allen DM; Ang PT
    Ann Acad Med Singap; 1994 Nov; 23(6):819-22. PubMed ID: 7741492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
    Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
    Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
    Biron P; Fuhrmann C; Cure H; Viens P; Lefebvre D; Thyss A; Viot M; Soler-Michel P; Rollin C; Grès JJ
    J Antimicrob Chemother; 1998 Oct; 42(4):511-8. PubMed ID: 9818751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Laboratory and clinical studies on imipenem/cilastatin sodium plus amikacin sulfate in patients with severe infections complicating hematological disorders].
    Hotta T; Morishima Y; Saito H; Kodera Y; Hirabayashi N; Tanaka M; Mizuno H; Suzuki H; Kato Y; Morishita Y
    Jpn J Antibiot; 1991 May; 44(5):515-28. PubMed ID: 1880931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients.
    Liu CY; Wang FD
    Chemotherapy; 1989; 35 Suppl 2():16-22. PubMed ID: 2692982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients.
    Liang R; Yung R; Chiu E; Chau PY; Chan TK; Lam WK; Todd D
    Antimicrob Agents Chemother; 1990 Jul; 34(7):1336-41. PubMed ID: 2201252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imipenem/cilastatin monotherapy as salvage treatment in febrile neutropenic patients.
    Engervall P; Günther G; Ljungman P; Lönnqvist B; Hast R; Stiernstedt G; Kalin M; Ringertz S; Björkholm M
    J Chemother; 1996 Oct; 8(5):382-6. PubMed ID: 8957719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
    Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
    Infection; 1996; 24(6):480-4. PubMed ID: 9007599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of three types of empirical antibiotherapy in patients with febrile neutropenia: imipenem-cilastatin versus ceftazidime-vancomycin versus ticarcillin-amikacin-vancomycin].
    Bosseray A; Nicolini F; Brion JP; Michallet M; Hollard D; Stahl JP; Micoud M
    Pathol Biol (Paris); 1992 Oct; 40(8):797-804. PubMed ID: 1484739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
    Vural S; Erdem E; Gulec SG; Yildirmak Y; Kebudi R
    Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients.
    Miller JA; Butler T; Beveridge RA; Kales AN; Binder RA; Smith LJ; Ueno WM; Milkovich G; Goldwater S; Marion A
    Clin Ther; 1993; 15(3):486-99. PubMed ID: 8364941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of imipenem/cilastatin sodium and fosfomycin as second-line combination chemotherapy in severe infections associated with hematologic disorders].
    Tsuda S; Kuzuyama Y; Nakai H; Seriu T; Takashima T; Tanaka S; Horiike S; Taniwaki M; Misawa S; Kashima K
    Jpn J Antibiot; 1993 Feb; 46(2):171-83. PubMed ID: 8331778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.